CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies

Key Points

The study aims to explore the relationship between α-Synuclein amplification and Alzheimer's biomarkers in dementia with Lewy bodies (DLB).
Analyzed a cohort of participants clinically diagnosed with DLB.
Investigated the association between α-Synuclein positivity and motor decline.
Evaluated the presence of Alzheimer Disease copathology and its impact on cognitive outcomes.
Found that α-Synuclein positivity correlates with increased motor decline.
Identified common occurrence of AD copathology in DLB patients.
AD copathology is associated with higher risks of cognitive and functional decline.

Observational study links α-Synuclein positivity to motor decline in dementia with Lewy bodies, suggesting cognitive risks with AD copathology.

No takes yet. Share an insight, caveat, or question.

Coughlin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share